DC-CIK过继细胞免疫治疗宫颈癌研究进展  

Progress on DC-CIK-based adoptive cellular immunotherapy for uterine cervical neoplasm

作　　者：吴慕云[1] 王希成[2] 

机构地区：[1]广东药学院临床医学院,广东广州510006 [2]广东药学院附属第一医院,广东广州510080

出　　处：《广东药学院学报》2013年第5期575-578,F0003,共5页Academic Journal of Guangdong College of Pharmacy

摘　　要：宫颈癌是女性生殖系统中最常见的恶性肿瘤之一,其发病率虽呈下降趋势但趋于年轻化。目前其治疗手段主要以手术、放疗和化疗为主,对于早期患者具有疗效,但中晚期效果不佳。过继细胞免疫治疗是一种新型治疗手段,以DC和CIK细胞为研究热点。现就DC-CIK过继细胞免疫治疗在宫颈癌方面的研究予以综述。Uterine cervical neoplasm is one of the most common malignant tumors in gynecology, which incidence has dropped but tends to younger. At present, the main treatment methods include operation, radiotherapy and chemotherapy, which is effective for the early patients but not quite effective for those of advanced stages. Adoptive cellular immunotherapy （ACI） is a new treatment method, of which dendritic cells （DC） and cytokine-indueed killer cells （CIK） are the research focus. Here is a review on the research of DC-CIK-based adoptive cellular immunotherapy for uterine cervical neoplasm.

关 键 词：DC CIK 过继细胞免疫治疗 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]